The HemOnc Pulse
Dr. Usmani Discusses Perseus, IsKia, Data Plus More Myeloma Updates
Dec 18, 2023
Dr. Saad Usmani, Chief of the Myeloma Service at the Memorial Sloan Kettering Cancer Center, discusses the evolution in myeloma treatment and highlights the Perseus and IsKia trials. The podcast also covers advancements in achieving MRD negativity, personalized therapy for translocation 1114 myeloma, autologous stem cell transplant, maintenance therapy, and mechanisms of resistance to BCMA and GPRC 5D directed therapies in myeloma.
27:37
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The Perseus trial reinforces the importance of incorporating anti-CD38 agents like DARA RVD in the induction phase of myeloma treatment for better patient outcomes.
- Real-world data presented at ASH 2023 highlights the potential of bi-specific antibodies in achieving deeper responses and possibly allowing chemotherapy-free treatments, but also emphasizes the need for careful monitoring due to infection risks.
Deep dives
Importance of Perseus Study in Changing Induction Treatment in Myeloma
The Perseus study presented at ASH 2023 highlights the significance of changing induction treatment in newly diagnosed myeloma patients. The study compared the efficacy of DARA RVD, followed by DARA land maintenance, with the standard RVD regimen. The results validate the use of combination therapies, specifically DARA RVD, as the preferred induction treatment, leading to improved progression-free survival (PFS) and enhanced depth of response. These findings support the need to consider adding anti-CD38 agents in the induction phase for optimal patient outcomes.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
